Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
02 Maio 2022 - 10:00AM
Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage
biopharmaceutical company pioneering the development of
exosome-based therapeutics as a new class of medicines, today
announced the appointment of David Mauro, M.D., Ph.D., a veteran
oncology and immunotherapy drug developer, as Chief Medical
Officer. Dr. Mauro will provide leadership and expertise for
Codiak’s pipeline of clinical development programs through
early-stage trials to global regulatory submissions and joins the
company’s Executive Leadership Team reporting to Douglas E.
Williams, Ph.D., President and CEO.
“We have been fortunate to work with David since
late last year in an advisory capacity and are delighted to welcome
him as Codiak’s Chief Medical Officer, particularly now that we are
on the cusp of bringing our third candidate into the clinic and
approaching key inflection points in our two ongoing clinical
trials,” said Dr. Williams. “David’s vast experience bringing
biologic and small molecule candidates through all stages of
development to regulatory submission will be tremendously valuable
to our clinical organization as we design the next-stage and future
registration-enabling trials to advance exosome-based therapies as
a promising new therapeutic modality.”
Dr. Mauro brings more than 20 years of oncology
drug development experience to Codiak, including directing
translational, early- and late-stage development for more than 25
Investigational New Drug candidates in the past decade. Most
recently, he served as chief medical officer of Prelude
Therapeutics, a clinical-stage biopharmaceutical company developing
targeted small molecule therapeutics for cancer. There, Dr. Mauro
oversaw all aspects of clinical development of five candidates,
including clinical operations, clinical pharmacology,
translational, statistics and regulatory affairs. Prior positions
include chief medical officer roles at two oncology immunotherapy
companies: Advaxis Immunotherapies and Checkmate Pharmaceuticals,
where he spent four years contributing to the development of the
company’s virus-like particle (VLP) platform for immunotherapy,
which contributed to the company’s recent acquisition by Regeneron
Pharmaceuticals. Earlier in his career, Dr. Mauro held positions of
increasing responsibility within the clinical and medical affairs
teams at Merck, Bristol Myers Squibb and Becton Dickinson. A
pharmacologist by training, Dr. Mauro earned a B.S. in biochemistry
from Cornell University, an M.D./Ph.D. from Temple University and
completed his residency in anatomic pathology at the National
Institutes of Health’s National Cancer Institute.
“I believe that the field of immunotherapy has
never been more exciting or promising in terms of the potential to
create truly innovative means of treating intractable forms of
cancer and other diseases,” said Dr. Mauro. “Codiak is at the
forefront of this with a modality and engineering platform that has
conceivably broad applications and the initial clinical data
support the foundational hypothesis that, by virtue of the inherent
characteristics of exosomes, they are capable of serving as the
basis of a new class of potentially transformative medicines.”
About Codiak BioSciences Codiak is
a clinical-stage biopharmaceutical company focused on pioneering
the development of exosome-based therapeutics, a new class of
medicines with the potential to transform the treatment of a wide
spectrum of diseases with high unmet medical need. By leveraging
the biology of exosomes as natural intercellular transfer
mechanisms, Codiak has developed its proprietary engEx Platform™ to
expand upon the innate properties of exosomes to design, engineer
and manufacture novel exosome therapeutic candidates. Codiak has
utilized its engEx Platform to generate a deep pipeline of
engineered exosomes aimed at treating a broad range of disease
areas, spanning oncology, neuro-oncology, neurology, neuromuscular
disease and infectious disease.
Forward-Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among other things, statements concerning the
development and therapeutic potential of the Company’s engEx
Platform, engEx product candidates and engineered exosomes
generally, including future development plans, regulatory filings,
data releases and timing with respect thereto. Any forward-looking
statements in this press release are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. For a discussion of these risks and
uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in Codiak’s Annual Report on Form 10-K for the year ended
December 31, 2021, and in subsequent filings with the
Securities and Exchange Commission, as well as discussions of
potential risks, uncertainties and other important factors in
Codiak’s subsequent filings with the Securities and Exchange
Commission. All information in this press release is current as of
the date of this report, and Codiak undertakes no duty to update
this information unless required by law.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/aca7a9c0-7508-4d6e-a687-c66d6e2c3aab
Investor Contact:
Christopher Taylor
VP, Investor Relations and Corporate Communications
T: 617-949-4220
E: investor@codiakbio.com
Media Contact:
Lindy Devereux
Scient PR
T: 646-515-5730
E: media@codiakbio.com
Codiak BioSciences (NASDAQ:CDAK)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Codiak BioSciences (NASDAQ:CDAK)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024